September 22, 2021 7:44am

Will the market’s anxiety and sector unease tighten your portfolio’s “bottom”?

Pre-open indications: 4 BUY and 3 SELL

What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity!

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.57% (+193 points), S&P futures are UP +0.52% (+23 point) and NASDAQ futures are UP +0.27% (+40 point)

 

U.S. stock futures were higher in early morning trading on Wednesday,

European stocks traded higher,

Asia pacific markets were down as Hong Kong and South Korea were closed for a holiday; Japan also fell while MSCI’s broadest index of Asia-Pacific shares outside Japan slipped 0.31%

 

Data Docket: Investors expect to hear details about when exactly the central bank plans to begin tapering its bond buying. Powell has previously said it could begin as soon as this year. That may not necessarily happen, however. <CNBC>

  • The Fed will release a policy statement with economic and interest rate forecasts at 2:30 p.m. ET.

 

Henry’omics:

Tuesday's stock market bounce fizzled although the stem, cell and gene therapy sector popped back from Monday’s debacle.

For markets, the Fed's latest decision will be one of this week's banner events, redirecting attention toward domestic monetary policy after fears over fallout from the potential default of Chinese property giant China Evergrande set off stocks' worst day since May earlier this week. (Yahoo Finance)

 

If you didn’t remember what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Q3/21:

  • September, 1 holiday, 7 positive and 7 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

Applied Genetic Technologies (AGTC) – reports Thursday, 9/23

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles: WHAT happened to the usual “pump/promote”?

  • Tuesday closed up +$0.25 with 654 shares traded following Monday closing down -$0.26 to $3.40 with 563 shares traded after last Friday’s 129 shares traded dropping the share price -$0.38 after Thursday closed -$0.04 with 14,641 shares traded

Question: WERE BSTG’s Q2 filing AUDITED by any accounting firm or left UNAUDITED for investors?

 

BUY:

bluebird bio (BLUE) closed up +$0.02 to $17.99 after Monday’s $ and has a positive +$0.48 or +2.67% aftermarket indication on news of completing the rolling submission of its Biologics License Application (BLA) to the U.S. FDA for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes.

CRISP Therapeutics (CRSP) closed up +$0.78 to $117.25 after Monday’s down -$8.05 to $116.47 after Friday’s +$7.10 to $124.52 and has a positive +$0.26 or +0.22% pre-market indication.

Global Blood Therapeutics (GBT) closed down -$0.10 to $27.00 after Monday’s $ with a positive +$0.53 or +1.96% aftermarket indication.

Intellia Therapeutics (NTLA) closed down -$0.62 to $147.25 after Monday’s -$8.93 to $148.36 after Friday’s +$3.44 to $157.29 and has a positive +$2.26 or +1.53% pre-open indication,

 

SELL:

Alnylam Pharmaceuticals (ALNY) closed up +$0.69 to $184.15 after Monday’s $183.46 with a negative -$0.40 or -0.22% aftermarket indication,

Regenxbio (RGNX) closed up +$0.65 to $44.23 after Monday’s $43.58 with a negative -$0.11 or -0.25% aftermarket indication,

 

The BOTTOM LINE: I’d … still be watching my portfolio’s “six” today, it is fraught with upcoming obstacles …

Not yielding, I keep reinforcing the theme that increased stock market volatility suppresses the stem, cell and gene therapy sector.

I maintain, the recent stem, cell and gene therapy sector investors should be a bit more defensive, limiting new buys and perhaps curtailing overexposure to electronic trading risks.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.